Tanezumab

Subcutaneous vs Intravenous Tanezumab for Knee, Hip Osteoarthritis

Subcutaneous vs Intravenous Tanezumab for Knee, Hip Osteoarthritis

By

Intravenous and subcutaneous administration of tanezumab may provide similar analgesia and tolerability in patients with hip or knee osteoarthritis.

First-in-Class Chronic Pain Drug Candidate Fast Tracked

First-in-Class Chronic Pain Drug Candidate Fast Tracked

By

Tanezumab is a NGF inhibitor and is a first-in-class agent to receive Fast Track approval.

Sign Up for Free e-Newsletters